INNOVATRIX CAPITAL

Our mission as a Next - Gen Insurtech disrupter is to maximise and facilitate investment in global life sciences for the social good through providing first of its kind risk transfer solutions for clinical trial failure.

Investment in Clinical Trials and Drug Development is high risk and low return with ineffective risk mitigation and attracting investment for much needed trials is a long standing challenge.

Innovatrix was established to change this by acting as a bridge between the Life Sciences and Risk Capital markets.

Our solutions are designed to provide downside risk protection for clinical trials failure through our suite of solutions that transfer the risk into the insurance and capital markets through model driven (parametric) and traditional indemnity based products. 

As part of its journey, Innovatrix has recently graduated from the prestigious Lloyd's of London Lab as part of cohort 9.  

Innovatrix is also ranked within the Top 20 European Insurtech Start ups in the Insuretech Connect Forward50 Europe report as at June 2023